Extended-release tablet manufacture and study announced by Dimerix

Dimerix, a drug discovery company, has announced a manufacturing schedule to start later this month for its extended release tablet of propagermanium, which will be used in the DMX-200 human PK study and Phase IIb trial in chronic kidney disease Read more

6 Sep 2017 11:27 News